Abstract
fraction 30%, left main or ostial location, major bifurcation disease, chronic total occlusion, and target vessel thrombus. Routine angiographic follow-up was not performed. Planned clinical follow-up is at 1, 6, 12, and 18 months, and annually to 5 years. Results: Patients were predominantly male (62.7%), and 30.0% presented with medically treated diabetes. At baseline, target lesion length was 24.38 8.21mm and reference vessel diameter was 2.56 0.40mm. The study met its primary endpoint of 12-month target lesion failure (composite of target vessel related cardiac death/MI and ischemia-driven target lesion revascularization) with a rate of 3.2%, which was not significantly different (p 0.001) than a prespecified performance goal of 19.4% (based on historical outcomes with 32mm paclitaxel-eluting stents, the only long drug-eluting stent approved in the US when PLATINUM LL was initiated). At 1-year follow-up, there were 3 instances of target lesion revascularization (3.1%), 1 non-cardiac death, and no cardiac deaths, MIs, or stent thromboses. Two-year clinical follow-up will be reported. Conclusions: The 1-year results of the PLATINUM LL study support the use of the PROMUS Element 32mm and 38mm stents in the treatment of long coronary lesions. Two-year results will be available for presentation for the first time at TCT in October 2012.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
